CV6 Therapeutics

1 known investors

CV6 Therapeutics develops investigational cancer therapies designed for combination use with established standards of care, with a lead program (CV6-168) intended to enhance the activity of 5-fluorouracil and other thymidylate synthase-targeted therapies. The company is advancing CV6-168 through Phase 1a clinical development.

BiotechHealthtech